SAVE SIGHT REGISTRIES PROJECT

Fight Tumour Blindness!

A web based registry for ocular melanoma, collecting clinical and pathology data to evaluate eye saving treatments and stratify patients for emerging systemic therapies.

OVERVIEW

A national registry for ocular melanoma

Launched
September 2018
Redeveloped
2022, with leading Australian uveal melanoma experts
Condition
Ocular (uveal) melanoma
Data
Clinical, pathology, treatment and follow up

Melanoma of the eye threatens both vision and life. The eye is the second most common site of melanoma after the skin, and uveal melanoma is fatal in approximately 50% of cases because of metastatic spread.

Cancer registries in Australia are state based and collect only minimum information. The data needed to understand recurrence, metastasis and treatment success in eye melanoma is missing.

Fight Tumour Blindness! is an Australian first: a web based registry that embeds research within health care delivery, as recommended by the McKeon Strategic Review of Health and Medical Research (2013).

RESEARCH AIMS

What the registry sets out to do

AIM 1

Collect high quality clinical and pathology data from patients with ocular melanoma.

AIM 2

Evaluate the outcomes of local, conservative eye saving treatments.

AIM 3

Stratify patients for appropriate emerging therapies to combat potentially fatal systemic disease.

CLINICAL CONTEXT

Current approaches to treatment

Where possible, primary eye melanoma is treated conservatively to preserve the eye and vision while controlling the tumour. Treatments are often successful but may reduce vision or result in loss of the eye.

Management is multidisciplinary and varies widely across Australia, which is why detailed diagnostic, treatment and follow up data is essential.

TREATMENT TYPICAL USE
Plaque brachytherapy The most common treatment, using iodine or ruthenium radiation, with or without customised plaque design and dosimetry planning
Trans scleral resection Anterior segment and ciliary body tumours
Endo resection Large posterior tumours
Transpupillary thermotherapy Thinner, pigmented tumours
Photodynamic therapy Thinner tumours

INVESTIGATOR

Leading Fight Tumour Blindness!

Dr Rod O’Day

CO INVESTIGATOR

Dr Rod O’Day

DMedSci, MBBS (Hons), LLB (Hons), BSc, FRANZCO

Head of Ocular Oncology Research, Centre for Eye Research Australia

Meet the full leadership team →